BAY-876 is a potent and selective inhibitor of the glucose transporter GLUT1 (SLC2A1). Its primary application lies in biomedical research, particularly in studying cancer metabolism. Many cancer cells rely heavily on glucose uptake through GLUT1 for energy production and survival, a phenomenon known as the Warburg effect. BAY-876 is used to block this glucose uptake, thereby inhibiting the growth and proliferation of cancer cells in vitro and in preclinical models. Researchers use BAY-876 to investigate the role of GLUT1 in tumor progression, metabolic reprogramming, and resistance to therapies. It has shown particular efficacy in models of cancers with high GLUT1 expression, such as certain leukemias, lung cancers, and glioblastomas. Additionally, BAY-876 serves as a tool compound to validate GLUT1 as a therapeutic target and to explore combination strategies with other anticancer agents, including chemotherapy and targeted therapies. Due to its selectivity, BAY-876 helps minimize off-target effects in experimental settings, making it valuable for mechanistic studies in cellular and molecular biology. While not yet used clinically, it supports the development of metabolic inhibitors as a new class of anticancer drugs.